Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study G Meyer, Z Marjanovic, J Valcke, B Lorcerie, Y Gruel, P Solal-Celigny, ... Archives of internal medicine 162 (15), 1729-1735, 2002 | 1062 | 2002 |
American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia A Cuker, GM Arepally, BH Chong, DB Cines, A Greinacher, Y Gruel, ... Blood advances 2 (22), 3360-3392, 2018 | 606 | 2018 |
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) P Knoebl, P Marco, F Baudo, P Collins, A Huth‐Kühne, L Nemes, ... Journal of Thrombosis and Haemostasis 10 (4), 622-631, 2012 | 579 | 2012 |
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals … G Pernod, P Albaladejo, A Godier, CM Samama, S Susen, Y Gruel, ... Archives of cardiovascular diseases 106 (6-7), 382-393, 2013 | 370 | 2013 |
Antibodies to platelet factor 4–heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical … C Pouplard, MA May, S Iochmann, J Amiral, AM Vissac, M Marchand, ... Circulation 99 (19), 2530-2536, 1999 | 362 | 1999 |
Evolution of blood coagulation activators and inhibitors in the healthy human fetus P Reverdiau-Moalic, B Delahousse, G Body, P Bardos, J Leroy, Y Gruel | 306 | 1996 |
Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent JC Gris, I Quéré, F Monpeyrou, E Mercier, S Ripart-Neveu, ML Tailland, ... Thrombosis and haemostasis 81 (06), 891-899, 1999 | 301 | 1999 |
Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis G Cayla, JS Hulot, SA O’Connor, A Pathak, SA Scott, Y Gruel, J Silvain, ... Jama 306 (16), 1765-1774, 2011 | 269 | 2011 |
Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin P Savi, BH Chong, A Greinacher, Y Gruel, JG Kelton, TE Warkentin, ... Blood 105 (1), 139-144, 2005 | 249 | 2005 |
Induction of monocyte tissue factor expression by antibodies to heparin–platelet factor 4 complexes developed in heparin-induced thrombocytopenia C Pouplard, S Iochmann, B Renard, O Herault, P Colombat, J Amiral, ... Blood, The Journal of the American Society of Hematology 97 (10), 3300-3302, 2001 | 237 | 2001 |
Prospective evaluation of the ‘4Ts’ score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin‐induced thrombocytopenia C Pouplard, P Gueret, M Fouassier, C Ternisien, M Trossaert, S Regina, ... Journal of Thrombosis and Haemostasis 5 (7), 1373-1379, 2007 | 231 | 2007 |
Decision analysis for use of platelet aggregation test, Carbon 14–Serotonin release assay, and heparin–platelet factor 4 Enzyme-Linked immunosorbent assay for diagnosis of … C Pouplard, J Amiral, JY Borg, S Laporte-Simitsidis, B Delahousse, ... American journal of clinical pathology 111 (5), 700-706, 1999 | 229 | 1999 |
Voltage-gated sodium channels potentiate the invasive capacities of human non-small-cell lung cancer cell lines S Roger, J Rollin, A Barascu, P Besson, PI Raynal, S Iochmann, M Lei, ... The international journal of biochemistry & cell biology 39 (4), 774-786, 2007 | 216 | 2007 |
Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin‐dependent antibodies C Pouplard, MA May, S Regina, M Marchand, J Fusciardi, Y Gruel British journal of haematology 128 (6), 837-841, 2005 | 210 | 2005 |
Determination of platelet antigens and glycoproteins in the human fetus Y Gruel, B Boizard, F Daffos, F Forestier, J Caen, JL Wautier | 183 | 1986 |
Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma … M Hunault-Berger, P Chevallier, M Delain, CE Bulabois, S Bologna, ... haematologica 93 (10), 1488-1494, 2008 | 181 | 2008 |
Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring S Susen, CA Tacquard, A Godon, A Mansour, D Garrigue, P Nguyen, ... Critical care 24 (1), 364, 2020 | 169 | 2020 |
Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216) J Leroy, MH Leclerc, B Delahousse, C Guerois, P Foloppe, Y Gruel, ... Seminars in thrombosis and hemostasis 11 (03), 326-329, 1985 | 159 | 1985 |
Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer J Rollin, S Régina, P Vourc’h, S Iochmann, C Bléchet, P Reverdiau, ... Lung cancer 56 (2), 273-280, 2007 | 149 | 2007 |
Laboratory testing for heparin‐induced thrombocytopenia: a conceptual framework and implications for diagnosis TE Warkentin, A Greinacher, Y Gruel, RH Aster, BH Chong Journal of Thrombosis and Haemostasis 9 (12), 2498-2500, 2011 | 140 | 2011 |